Raymond James & Associates’s Foghorn Therapeutics FHTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $21.4M | Sell |
2,297,319
-41,104
| -2% | -$383K | 0.01% | 783 |
|
|
2024
Q2 | $13.4M | Buy |
2,338,423
+107,967
| +5% | +$621K | 0.01% | 992 |
|
|
2024
Q1 | $15M | Buy |
2,230,456
+162,069
| +8% | +$1.09M | 0.01% | 926 |
|
|
2023
Q4 | $13.3M | Buy |
2,068,387
+642,161
| +45% | +$4.14M | 0.01% | 937 |
|
|
2023
Q3 | $7.13M | Buy |
1,426,226
+235,237
| +20% | +$1.18M | 0.01% | 1244 |
|
|
2023
Q2 | $8.38M | Buy |
1,190,989
+112,933
| +10% | +$795K | 0.01% | 1158 |
|
|
2023
Q1 | $6.68M | Buy |
1,078,056
+533,123
| +98% | +$3.31M | 0.01% | 1269 |
|
|
2022
Q4 | $3.48M | Buy |
544,933
+515,796
| +1,770% | +$3.29M | ﹤0.01% | 1665 |
|
|
2022
Q3 | $250K | Buy |
29,137
+1,000
| +4% | +$8.58K | ﹤0.01% | 3276 |
|
|
2022
Q2 | $383K | Buy |
28,137
+2,000
| +8% | +$27.2K | ﹤0.01% | 3055 |
|
|
2022
Q1 | $398K | Buy |
26,137
+13,200
| +102% | +$201K | ﹤0.01% | 3190 |
|
|
2021
Q4 | $296K | Buy |
+12,937
| New | +$296K | ﹤0.01% | 3430 |
|